In the KEYNOTE-024 trial published in 2017, patients with advanced stage NSCLC with tumor PD-L1 expression of 50% or more were randomized to receive pembrolizumab or platinum-based chemotherapy. The gene discussed is CD274; the disease is neoplasm.